13/02/2018 15:47:00

Alder BioPharmaceuticals, Inc. Announces Exercise in Full of Underwriters’ Option to Purchase Additional 2.50% Convertible Senior Notes Due 2025

Related content
07 Aug - 
Alder BioPharmaceuticals® Reports Second Quarter 2018 F..
02 Aug - 
Alder BioPharmaceuticals® to Present at the Canaccord G..
31 Jul - 
Alder BioPharmaceuticals® to Host Conference Call to Di..

BOTHELL, Wash., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that the underwriters of its previously announced offering of 2.50% convertible senior notes due 2025 (the “Notes”) have exercised in full their option to purchase up to an additional $37.5 million aggregate principal amount of Notes, solely to cover over-allotments, for a total offering of $287.5 million in aggregate principal amount. The sale of additional Notes closed on February 13, 2018.

Alder intends to use net proceeds from the offering to fund the development and commercialization of eptinezumab, and in particular, activities in support of achieving approval by the U.S. Food and Drug Administration for, and executing the commercial launch of, the infusion formulation of eptinezumab.

Goldman Sachs & Co. LLC, Leerink Partners LLC and Wells Fargo Securities, LLC acted as book-running managers for the offering.

A shelf registration statement relating to the offering was filed with the Securities and Exchange Commission (the “SEC”), and was effective on filing on February 23, 2017.  A final prospectus supplement and the accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC's website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone toll-free at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate, 375 Park Avenue, New York, New York 10152, by telephone toll-free at 800-326-5897 or by email at cmclientsupport@wellsfargo.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Alder’s anticipated use of net proceeds from the offering, and the continued development and commercialization of eptinezumab. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Alder is contained in the section captioned "Risk Factors" in the final prospectus supplement related to the public offering filed with the SEC and other filings with the SEC from time to time. Alder disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:

Ashley Cadle

TogoRun

310-463-0143

a.cadle@togorun.com

 

Investor Relations Contact:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Sophos Sweeps Network and Endpoint Security Categories in CRN’s 2018 Annual Report Card – Again!
2
SHAREHOLDER ALERT: FIZZ ACAD FB ABBV TTPH RMTI HMNY GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
3
SHAREHOLDER ALERT: MRCY GLCNF GLNCY MD COOL HAIR FPI SBGL NWL GOGO FLKS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
4
Key Energy Services Announces Appointment of Rob Saltiel as New President and Chief Executive Officer
5
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 August 2018 13:33:16
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180816.1 - EUROWEB5 - 2018-08-20 14:33:16 - 2018-08-20 13:33:16 - 1000 - Website: OKAY